BT Pharma, a specialist in immunotherapeutics for human papilloma virus (HPV) -associated diseases and cancers, closed a Euro 2,825,000 round was led by Edmond de Rothschild Investment Partners (EdRIP).
Longstanding shareholders Fonds d'Amorçage Midi-Pyrenees (FAM) managed by the team of Icso Private Equity, BrevImmo, LBP, Beaufagne, Whitehall and the Management of the company followed on. The money will enable the company to take its lead immunotherapeutic candidate, ProCervix, through the final stages of its preclinical development and prepare it to enter into clinical trials.
ProCervix is intended to treat women who are infected by Human Papillomavirus and who therefore run the risk of developing high-grade neoplasia and/or cervical cancer.
The product uses an Adenylate Cyclase viral vector, which has the ability to selectively delivering antigens into the appropriate immune cell. This results in the activation of a strong and specific cellular immune response against HPV.
BT Pharma was incorporated in October 2001 and spun out of the Institut Pasteur in October 2002.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
